124 Results for "

auristatin

" in MedChemExpress (MCE) Product Catalog:
Products (124)

124 Results for "auristatin" in MCE Product Catalog:

97
97 Publications Verification
Cat. No.: HY-15575
CAS No.: 646502-53-6
Purity:  99.94%
Synonyms: MC-Val-Cit-PAB-MMAE; mc-vc-PAB-MMAE; Vedotin
VcMMAE (mc-vc-PAB-MMAE) is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).
loading...
    loading...
61
61 Cited Publications
Cat. No.: HY-15162
CAS No.: 474645-27-7
Purity:  99.97%
Synonyms: MMAE; SGD-1010
Research Areas:  

Cancer

Monomethyl auristatin E (MMAE; SGD-1010) is a synthetic derivative of dolastatin 10 and functions as a potent mitotic inhibitor by inhibiting tubulin polymerization. MMAE is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) to treat several different cancer types.
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-15162A
CAS No.: 2070009-72-0
Purity:  99.15%
Synonyms: Monomethyl auristatin E-d8; Deuterated labeled MMAE
MMAE-d8 is a deuterated labeled MMAE, a potent mitotic inhibitor and a tubulin inhibitor.
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-15578
CAS No.: 863971-19-1
Purity:  99.96%
Synonyms: Maleimidocaproyl monomethylauristatin F
Research Areas:  

Cancer

McMMAF (Maleimidocaproyl monomethylauristatin F) is an active molecule linker for ADC, made by coupling the powerful microtubule inhibitor Monomethyl auristatin F (MMAF) (HY-15579) with the protecting group maleimidocaproyl. McMMAF can be conjugated with anti-BCMA antibodies to form J6M0-mcMMAF, promoting apoptosis and inhibiting tumor growth .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-P9985
CAS No.: 2136633-23-1
Synonyms: RC48
Research Areas:  

Cancer

Disitamab vedotin (RC48) is a HER2-targeted antibody-drug conjugate (ADC), formed by conjugation of the humanized anti-HER2 antibody Disitamab (HY-P99854) with drug-linker VcMMAE (HY-15575). VcMMAE consists of a cleavable MC-Val-Cit-PAB linker and the microtubule inhibitor MMAE (HY-15162). After binding to HER2 and undergoing endocytosis, Disitamab vedotin releases MMAE in lysosomes, which further inhibits microtubule assembly, arrests mitosis and induces apoptosis, while also exerting a bystander effect. Disitamab vedotin can be used in studies of HER2-positive breast cancer .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-100566
Purity:  99.24%
Research Areas:  

Cancer

SuO-Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the peptide SuO-Val-Cit-PAB .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-111012
CAS No.: 2754384-60-4
Purity:  99.60%
Research Areas:  

Cancer

DBCO-(PEG)3-VC-PAB-MMAE is a agent-linker conjugate for ADC. DBCO-(PEG)3-VC-PAB-MMAE is made by Monomethyl auristatin E (HY-15162) conjugats to DBCO-(PEG)3-vc-PAB linker. DBCO-(PEG)3-VC-PAB-MMAE can be used for the research of cancer . DBCO-(PEG)3-VC-PAB-MMAE is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99151
CAS No.: 2088770-90-3
Synonyms: CAC-10

Research Areas:  

Cancer

Brentuximab (CAC-10) is a chimeric antibody targeting CD30. Brentuximab is conjugated with Monomethyl auristatin E (MMAE) (HY-15162) to form the antibody-drug conjugate Brentuximab vedotin (HY-P99107A). Brentuximab can be used for the research of cancer, such as lymphoma .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-141601
CAS No.: 1714088-51-3
Purity:  99.90%
Synonyms: ABBV-399
Telisotuzumab vedotin (ABBV-399) (Teliso-V) is an anti-c-Met antibody-drug conjugate. Telisotuzumab vedotin consists of an anti-c-Met monoclonal antibody Telisotuzumab (ABT-700) (HY-P99391) and Monomethyl Auristatin E (HY-15162). Telisotuzumab vedotin exerts antitumor activity with acceptable toxicity in vivo. Telisotuzumab vedotin can be used for non-small cell lung cancer (NSCLC) research .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-126681
CAS No.: 2259318-46-0
Purity:  98.01%
Synonyms: NHS-VC-PAB-MMAE
Research Areas:  

Cancer

SC-VC-PAB-MMAE (NHS-VC-PAB-MMAE) is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the cleavable linker SC-VC-PAB .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-12522S
CAS No.: 3020284-76-5
Purity:  99.37%
Synonyms: Aur0101-d8; auristatin-0101-d8
PF-06380101-d8 (Aur0101-d8) is a deuterium labeled PF-06380101 (HY-12522). PF-06380101, an Auristatin microtubule inhibitor, is a cytotoxic Dolastatin 10 analogue .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P81056
Synonyms: MMAE; Monomethyl auristatin E; Monomethylauristatin E; Monomethylauristatin norephedrine; Toxin MMAE; MMAE toxin

Host:  

Rabbit

Application:  

ELISA

Reactivity:  

Species independent

loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99205
CAS No.: 1020264-78-1

Target:  

ADC Antibodies

Research Areas:  

Cancer

Glembatumumab is a fully human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. Glembatumumab can be coupled to the microtubule inhibitor monomethyl auristatin E to form glembatumumab vedotin. Glembatumumab vedotin is an antibody-agent coupling (ADC) with antitumor activity .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-79256
CAS No.: 863971-12-4
Synonyms: Monomethyl auristatin F methyl ester
Target:  

ADC Payloads

Research Areas:  

Cancer

MMAF-Ome, an antitubulin agent, is also an ADC cytotoxin. MMAF-Ome inhibits several tumor cell lines with IC50s of 0.056 nM, 0.166 nM, 0.183 nM, and 0.449 nM for MDAMB435/5T4, MDAMB361DYT2, MDAMB468, and Raji (5T4 -) cell lines, respectively.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-132253
CAS No.: 1313206-42-6
Purity:  98.83%
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-128955
CAS No.: 1438849-92-3
Purity:  99.66%
Research Areas:  

Cancer

MC-VC-PABC-Aur0101 is a agent-linker conjugate for ADC with potent antitumor activity by using Aur0101 (an auristatin microtubule inhibitor), linked via the ADC linker MC-VC-PABC.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-132253A
CAS No.: 1313206-42-6
Purity:  98.36%
Polatuzumab vedotin solution is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin solution has the potential for the research of Large B-cell lymphomas (LBCL) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-14672
CAS No.: 149606-27-9
Purity:  99.29%
Synonyms: auristatin PE; TZT-1027
Target:  

Microtubule/Tubulin

Research Areas:  

Cancer

Soblidotin (Auristatin PE) is a novel synthetic Dolastatin 10 derivative and inhibitor of tubulin polymerization.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99107A
CAS No.: 914088-09-8
Research Areas:  

Cancer

Brentuximab vedotin (solution) (cAC10-vcMMAE) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E (MMAE). The antibody portion is Brentuximab (HY-P99151), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Brentuximab vedotin (solution) inhibits CD30-positive cells with an IC50 of 2.5 ng/mL. Brentuximab vedotin (solution) can be used for the research of relapsed and refractory Hodgkin lymphoma .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-W190943
CAS No.: 1869126-64-6
Research Areas:  

Cancer

Azido-PEG4-Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the cleavable linker Azido-PEG4-Val-Cit-PAB-OH . Azido-PEG4-Val-Cit-PAB-MMAE is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
loading...
    loading...